MQS Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

MQS Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,935	Closed	-$255K	–	334
2021 Q4	$255K	Buy	+10,935	New	+$224K	0.41%	119

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

MQS Management's AMPH Position: Q1 2022 in Review

MQS Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2022, closing a stake of 10,935 shares — an estimated $255K sold.

MQS Management first reported a position in AMPH in Q4 2021 and held it in 1 quarter. The position peaked at $255K in Q4 2021. 203 funds tracked by Wall St. Rank hold AMPH as of Q1 2022.

MQS Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
MQS Management sold 10,935 Amphastar Pharmaceuticals shares in Q1 2022, an estimated $255K.
MQS Management first reported a position in Amphastar Pharmaceuticals in Q4 2021 and held it in 1 quarter.
MQS Management's Amphastar Pharmaceuticals position peaked at $255K in Q4 2021.
203 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2022.

Based on MQS Management's 13F filing for Q1 2022, filed 10 May 2022.